Evaluation of the Rimonabant Impact on the Regression of Asymptomatic Damage Caused by Cardiovascular Risk Factors

Stopped Company decision has been taken in light of recent demands by certain national health authorities

Conditions

• Obesity
• Microalbuminuria
• Diabetes Mellitus, Type 2
• Dyslipidemia

Interventions

• DRUG: Rimonabant
• DRUG: Placebo

Sponsor

Sanofi